Digital application for improving quality of life in acute leukemia patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This research evaluates the efficacy of a self-administered digital application called DREAMLAND, designed to enhance the long-term quality of life and psychological outcomes for patients with acute myeloid leukemia (AML) undergoing intensive chemotherapy. The app includes four modules focusing on supportive psychotherapy, psychoeducation, psychosocial skill-building, and self-care to help patients cope with the challenges of their diagnosis and treatment. The study targets newly diagnosed AML patients who face significant physical and psychological distress during their hospitalization for chemotherapy. By providing a scalable digital intervention, the study aims to address the limited availability of supportive care for these patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Hospitalized patients (age \> 18 years) with a diagnosis of AML.
* Initiating treatment with either a) intensive chemotherapy (7+3) or modification of this regimen on a clinical trial, or a similar intensive regimen or b) hypomethylating agents (HMA) +/- additional agents or modification of this regimen on a clinical trial.
* Ability to comprehend and speak English as the digital apps are only available in English

Note: Patients newly diagnosed as well as those with relapsed/refractory AML initiating treatment with intensive or HMA-based chemotherapy will be eligible to participate.

Exclusion Criteria:

* Patients with a diagnosis of acute promyelocytic leukemia
* Patients with acute or unstable psychiatric or cognitive conditions which the treating clinicians believes prohibits informed consent or compliance with study procedures.

Where it's running

• Massachusetts General Hospital (MGH)
  Boston, Massachusetts, United States Recruiting
• Duke University
  Durham, North Carolina, United States Not yet recruiting
• Fred Hutchinson Cancer Research Center (FHCRC)
  Seattle, Washington, United States Not yet recruiting

Study contacts

• Study coordinator: Areej El-Jawahri, MD
• Email: ael-jawahri@mgb.org
• Phone: 617-724-4000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing two types of palliative care for patients with acute myeloid leukemia

  This study is testing if regular palliative care can help hospitalized patients with acute myeloid leukemia feel better and cope with their illness just as well as specialty palliative care.

  Recruiting at 20 sites Massachusetts General Hospital · Birmingham, Alabama and 19 other locations · NCT05237258

• Donor γδ T cell infusion to prevent relapse after stem cell transplant in high‑risk AML

  This will test whether a donor γδ T cell infusion given soon after an allogeneic stem cell transplant can help prevent relapse in adults (18–65) with high‑risk acute myeloid leukemia.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT07237230

• Venetoclax-enhanced BUCY versus standard BUCY conditioning for high‑risk AML and MDS before allogeneic stem cell transplant

  This will test whether adding venetoclax to BUCY conditioning before allogeneic stem cell transplant helps patients aged 12–60 with high‑risk AML or MDS stay in remission longer.

  Recruiting First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang · NCT07183878

• Using CD45RA Depleted Stem Cells to Prevent Infections After Transplant

  This study is testing whether using special stem cells can help patients with high-risk leukemia recover their immune system faster and prevent infections after a stem cell transplant.

  Recruiting Phase 1/2 Children's Hospital of Philadelphia · Philadelphia, Pennsylvania · NCT06839456

• Combining venetoclax and azacitidine with HAAG for treating newly diagnosed AML

  This study is testing a new combination of medications for people who have just been diagnosed with intermediate and high-risk acute myeloid leukemia to see if it helps them respond better to treatment.

  Recruiting Phase 2 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT06394011

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.